Compare CREX & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CREX | INMB |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.3M | 39.6M |
| IPO Year | 2015 | 2018 |
| Metric | CREX | INMB |
|---|---|---|
| Price | $3.21 | $2.05 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.40 |
| AVG Volume (30 Days) | 44.2K | ★ 1.1M |
| Earning Date | 04-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 2.86 | ★ 11.85 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $18,437,000.00 | $50,000.00 |
| Revenue This Year | $81.98 | N/A |
| Revenue Next Year | $14.82 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 5.61 | ★ 257.14 |
| 52 Week Low | $2.19 | $1.09 |
| 52 Week High | $4.42 | $3.24 |
| Indicator | CREX | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 32.11 | 71.66 |
| Support Level | $3.05 | $1.21 |
| Resistance Level | $3.86 | $2.30 |
| Average True Range (ATR) | 0.32 | 0.17 |
| MACD | -0.10 | 0.04 |
| Stochastic Oscillator | 1.69 | 82.78 |
Creative Realities Inc, along with its subsidiaries, is engaged in providing digital marketing technology & solutions to world-wide retail companies, luxury and other individual retail brands, advertising networks, outdoor clients, enterprises, and other organizations. The company operates in one reportable segment, marketing technology solutions. It offers solutions related to digital merchandising systems, omnichannel customer engagement systems, interactive digital shopping assistants, advisors and kiosks, and high-end audio-visual networks, along with marketing technologies such as mobile, social media, point-of-sale transactions, beaconing, and web-based media. Geographically, the company generates maximum revenue from the United States, and the rest from Canada.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.